The earnings call presented a generally positive outlook for Certara, driven by strong revenue and bookings growth, the launch of new software versions, and the FDA's announcement favoring their product offerings. While market headwinds and specific segment softness were noted, the company's strategic initiatives and new opportunities seemed to outweigh the challenges.

Company Guidance -

Q1 2025

During Certara's First Quarter 2025 Earnings Conference Call, significant guidance was provided detailing the company's financial performance and future outlook. Certara reported first-quarter revenue of $106 million, reflecting a 10% increase from the same period in 2024. Bookings for the quarter were $118.2 million, up 12% year-over-year, with software bookings growing by 23% and services bookings by 7%. Chemaxon significantly contributed $5.9 million to revenue and $4.9 million to bookings. The guidance for the full year anticipates total revenue between $415 million and $425 million, with Chemaxon expected to contribute $23 million to $25 million. Adjusted EBITDA margins are projected to be between 30% and 32%, with adjusted EPS in the range of $0.42 to $0.46. Certara emphasized strategic investments in AI integration and biosimulation model development, particularly in response to the FDA's recent move to phase out animal testing, which is expected to positively impact the company's future growth trajectory.

Strong Revenue and Bookings Growth

Certara reported first quarter revenue of $106 million, representing a 10% growth compared to Q1 2024. Bookings reached $118.2 million, a 12% increase from the previous year.

Significant Software Segment Performance

Software revenue for Q1 2025 was $46.4 million, an 18% increase from the prior year, with software bookings growing by 23%. Chemaxon contributed $5.9 million to software revenue.

FDA Announcement on Animal Testing Phase-Out

The FDA's announcement to phase out animal testing has led to significant interest in Certara's Non-Animal Navigator solution, which leverages AI and modeling to replace animal testing in drug development.

Launch of Simcyp Simulator Version 24

Certara announced the 24th version of its Simcyp Simulator, featuring new drug interaction libraries and enhanced modeling capabilities. Simcyp has supported over 120 FDA-approved novel drug applications.

Share Repurchase Program

Certara announced a $100 million share repurchase authorization, with approximately $25 million repurchased to date, reflecting confidence in the company's long-term growth strategies.

Adjusted EBITDA Growth

Adjusted EBITDA for Q1 2025 was $34.8 million, up from $29.1 million in Q1 2024, with a margin of 33%.

Certara (CERT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CERT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2025	2025 (Q2)	0.09 / -	0.07	―	―	―
May 05, 2025	2025 (Q1)	0.11 / 0.14	0.1	40.00% (+0.04)
Feb 26, 2025	2024 (Q4)	0.12 / 0.15	0.09	66.67% (+0.06)
Nov 06, 2024	2024 (Q3)	0.11 / 0.13	0.11	18.18% (+0.02)
Aug 06, 2024	2024 (Q2)	0.10 / 0.07	0.12	-41.67% (-0.05)
May 07, 2024	2024 (Q1)	0.10 / 0.10	0.12	-16.67% (-0.02)
Feb 29, 2024	2023 (Q4)	0.11 / 0.09	0.16	-43.75% (-0.07)
Nov 08, 2023	2023 (Q3)	0.11 / 0.11	0.1	10.00% (<+0.01)
Aug 09, 2023	2023 (Q2)	0.13 / 0.12	0.09	33.33% (+0.03)
May 08, 2023	2023 (Q1)	0.12 / 0.12	0.11	9.09% (<+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CERT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 05, 2025	$12.78	$11.37	-11.03%
Feb 26, 2025	$12.33	$12.40	+0.57%
Nov 06, 2024	$10.91	$10.99	+0.73%
Aug 06, 2024	$15.08	$13.03	-13.59%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Certara (CERT) report earnings?

Certara (CERT) is schdueled to report earning on Aug 12, 2025, After Close (Confirmed).

What is Certara (CERT) earnings time?

Certara (CERT) earnings time is at Aug 12, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CERT EPS forecast?

CERT EPS forecast for the fiscal quarter 2025 (Q2) is 0.09.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing